Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Ming Yi, Xiaoli Zheng, Mengke Niu, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 828

Showing 1-25 of 828 citing articles:

Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 431
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang Qing, Yun Chen, Xiaojuan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 275
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
Jiqin Zhang, Yongxian Hu, Jiaxuan Yang, et al.
Nature (2022) Vol. 609, Iss. 7926, pp. 369-374
Open Access | Times Cited: 222
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Hao Zhang, Lin Liu, Jinbo Liu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 159
Breast cancer heterogeneity and its implication in personalized precision therapy
Liantao Guo, Deguang Kong, Jianhua Liu, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 139
Tumor organoids: applications in cancer modeling and potentials in precision medicine
Hanxiao Xu, Dechao Jiao, Aiguo Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 134
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 134
Emerging Sonodynamic Therapy‐Based Nanomedicines for Cancer Immunotherapy
Yunrong Yang, Jia Huang, Min Liu, et al.
Advanced Science (2022) Vol. 10, Iss. 2
Open Access | Times Cited: 132
Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Yanyan Xu, Jingyuan Xiong, Xiyang Sun, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 12, pp. 4327-4347
Open Access | Times Cited: 123
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
Kun Pang, Zhenduo Shi, Liuya Wei, et al.
Drug Resistance Updates (2022) Vol. 66, pp. 100907-100907
Closed Access | Times Cited: 113
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Qian Li, Jingjing Han, Yonglin Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 112
Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity
Yuheng Yan, Lan Huang, Yiming Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 108
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
Hany E. Marei, Anwarul Hasan, Giacomo Pozzoli, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 107
Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 103
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Kunyu Shi, Guan Wang, Junping Pei, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 101
Nanomaterials in tumor immunotherapy: new strategies and challenges
Xudong Zhu, Shenglong Li
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 101
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Ming Yi, Mengke Niu, Yuze Wu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 100
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
Jin-Ling Huo, Yatao Wang, Wen-Jia Fu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 99
Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 96
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Ming Yi, Yuze Wu, Mengke Niu, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 12, pp. e005543-e005543
Open Access | Times Cited: 95
Molecular and functional imaging in cancer-targeted therapy: current applications and future directions
Jing‐Wen Bai, Si-Qi Qiu, Guo‐Jun Zhang
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 93
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
Xianjing Chu, Wentao Tian, Ziqi Wang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 86
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 78
Cancer stem cells: advances in knowledge and implications for cancer therapy
Xianjing Chu, Wentao Tian, Jiaoyang Ning, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 73
PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Adil Parvez, Furqan Choudhary, Priyal Mudgal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 67
Page 1 - Next Page

Scroll to top